top of page
Our Pipeline
We are developing transformative cancer therapies with our best-in-class tumor-activated PrimeBody platform, utilizing de-risked components, assembled with novel masking and protein engineering approaches:
PrimeBody | Target(s) | Indication(s) | Discovery | Lead optimization | IND enabling | Phase 1 |
|---|---|---|---|---|---|---|
High-affinity CD47 blocker, Fc-enhanced | CD47 | Colon, gastric, prostate, bladder, lung, ovarian cancers | ||||
Immunocytokine with sustained signaling | Cytokine x Target (bispecific) | Solid tumors |
bottom of page